Search results for "remission"

showing 10 items of 213 documents

Uncommon presentation of pigmented paraungual basal cell carcinoma on the first toe treated with total excision

2020

Basal cell carcinomas (BCCs) are the most common types of skin neoplasm. The finger, toe, and nail unit are uncommon and rare locations of BCC. Only a few patients with foot BCC have been reported, and ungual BCC is even less frequent. We present a patient with a BCC on the left first toe. Clinically, it appeared as a brown-colored plaque with an irregular border on the nail fold and dorsum of the left thumb. Histopathological findings were consistent with the pigmented type of BCC. Surgical approach with subsequent full thickness mesh graft led to a complete remission. Follow-up at 10 months revealed a functionally and cosmetically acceptable outcome. The clinical presentation of nail unit…

medicine.medical_specialtySkin Neoplasmintegumentary systemUngualbusiness.industryfungiComplete remissionLeft thumbDermatologyGeneral Medicinemedicine.diseaseDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisNail (anatomy)medicineMesh graftBasal cell carcinomaPresentation (obstetrics)skin and connective tissue diseasesbusinessDermatologic Therapy
researchProduct

Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-anal…

2019

Background & Aims: Risk for relapse after induction of remission with steroid therapy has been studied extensively in patients with autoimmune pancreatitis (AIP), but findings have been equivocal. We performed a systematic review and meta-analysis to estimate the relapse rate of AIP after initial remission after steroid treatment and to identify factors associated with relapse. Methods: Three reviewers searched MEDLINE, SCOPUS, and EMBASE until July 2018 to identify studies on rate of relapse of AIP after induction of remission with steroid therapy. A pooled estimate was calculated using the DerSimonian and Laird method for a random-effects model. This study was conducted in accordance …

medicine.medical_specialtyTime FactorsAutoimmune Pancreatitismedicine.medical_treatmentMEDLINEInflammation; Long-Term Outcome; Pancreas; Response To TreatmentSteroidlaw.invention03 medical and health sciences0302 clinical medicineMaintenance therapyRandomized controlled trialRecurrenceRisk FactorslawInternal medicinemedicineHumansPancreaIn patientGlucocorticoidsPancreasAutoimmune pancreatitisInflammationHepatologybusiness.industryRemission InductionResponse To TreatmentGastroenterologyLong-Term Outcomemedicine.diseaseSystematic review030220 oncology & carcinogenesisMeta-analysisChronic Disease030211 gastroenterology & hepatologybusinessFollow-Up StudiesClinical Gastroenterology and Hepatology
researchProduct

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

2020

Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS). The short-term response was assessed at week 4, 8 and 16. The last-observation-carried-forward method was used in patients that stopped tofacitinib before the time-points for clinical assessment. Variables associated with short-term remission at week 8 were identified by logistic regression analysis. The cumulative retention rate and the cumulative incidence o…

medicine.medical_specialtyTofacitinibbusiness.industryHypertriglyceridemiaGastroenterologyGeneral MedicineReal world evidencemedicine.diseaseUlcerative colitisInternal medicineDisease remissionmedicinePredictor variableAdverse effectbusinessSurvival analysisJournal of Crohn's and Colitis
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

2005

The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five…

medicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentIntelligenceBrain tumorNeuropsychological TestsCarboplatinchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCerebellar NeoplasmsCyclophosphamideEtoposideEtoposideProportional Hazards ModelsMedulloblastomaPostoperative CareChemotherapyAnalysis of Variancebusiness.industryDesmoplastic medulloblastomaRemission InductionInfantGeneral Medicinemedicine.diseaseSurvival AnalysisCarboplatinSurgeryMethotrexatechemistryChemotherapy AdjuvantVincristineChild PreschoolNeoplasm Recurrence Localbusinessmedicine.drugFollow-Up StudiesMedulloblastomaThe New England journal of medicine
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct

FRI0056 Joint damage in patients with rheumatoid arthritis over 15-20 years – are there differences between women and men?

2013

Background Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women and men meet remission criteria more often than women do. Long-term severity of RA can be analyzed from permanent joint damage in radiographs. Objectives To study possible differences in the extent of radiographic joint damage between women and men in four early RA cohorts with 15 or more years of prospective follow-up. Methods Early RA cohorts with prospective longitudinal observations include following cohorts: Jyvaskyla Central Hospital with 70 patients from 1990’s (JYV1990) and 135 patients from the 1980’s (JYV1980), Lund University Hospital with…

medicine.medical_specialtybusiness.industryImmunologySevere diseasemedicine.diseaseUniversity hospitalGeneral Biochemistry Genetics and Molecular BiologySurgeryRheumatologyRemission criteriaRheumatoid arthritisInternal medicineJoint damageEarly ramedicineImmunology and AllergyIn patientbusinessRheumatismAnnals of the Rheumatic Diseases
researchProduct

Clinical Syndromes, Pathogenesis, and Differential Diagnosis

1991

The temporal sequence of signs and symptoms in patients with cerebral ischemia provides important information for the analysis of underlying pathophysiologic mechanisms and in the search for a major hemodynamic or embolic cause. The signs reported and symptoms assessed are useful for localization of the ischemic region of the brain and identification of the affected vascular territories. Even in the case of a typical clinical picture the clinical findings alone are often insufficient for unequivocal anatomic and pathologic identification, however important they may be in the choice of diagnostic and therapeutic measures. In the first few hours after cerebral ischemia, determining the progno…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentIschemiaHemodynamicsSpontaneous remissionThrombolysisPosterior cerebral arterymedicine.diseasePathogenesismedicine.arteryInternal medicinemedicineBasilar arteryCardiologyDifferential diagnosisbusiness
researchProduct

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective …

2018

Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previ…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiescomplete remissionImmunologylenalidomideadverse eventContext (language use)dexamethasoneBiochemistrychemistry.chemical_compoundMedian follow-upInternal medicinemedicinecarfilzomib dexamethasone lenalidomide multiple myeloma toxic effect adverse event bortezomib complete remission erythropoietin febrile neutropeniaMultiple myelomaLenalidomidetoxic effectcarfilzomibbusiness.industryCumulative dosebortezomibCell BiologyHematologymedicine.diseaseCarfilzomibmultiple myelomaRegimenfebrile neutropeniachemistryerythropoietinbusinessFebrile neutropeniamedicine.drug
researchProduct